Vivo Bio Tech Q1 Results FY27: PAT Falls 85.97% Despite Revenue Growth of 14.13%
- July 14, 2026
- Posted by: Neeraj Pandey
- Category: News
Vivo Bio Tech Q1 FY27: PAT Rs 0.19 Cr, down 85.97% YoY. Revenue Rs 14 Cr, up 14.13%. Gross profit Rs 1 Cr, down 46.55%. Stock at Rs 24.15, down 4.13% on 13 July 2026.
Vivo Bio Tech Q1 results FY27 were announced on Monday, 13 July 2026, with the Hyderabad based drug development and preclinical research services company reporting a standalone net profit of Rs 0.19 crore, down 85.97% from Rs 1 crore in the year ago quarter. Revenue in the Vivo Bio Tech Q1 results FY27 grew 14.13% year on year to Rs 14 crore from Rs 12 crore, even as gross profit fell 46.55% to around Rs 1 crore.
Shares of Vivo Bio Tech fell 4.13% to close at Rs 24.15, with the market reacting to the sharp profit decline despite the healthy revenue growth, a disconnect that points to significant margin pressure during the quarter.
Click Here – Get Free Investment Predictions
Vivo Bio Tech Q1 results FY27 Financial Highlights
The June quarter showed revenue growth alongside a sharp profit collapse, a combination that defines the Vivo Bio Tech Q1 results FY27. The table below summarises the standalone numbers against the year ago quarter, in rounded crore terms.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 14 Cr | Rs 12 Cr | +14.13% |
| Gross Profit | Rs 1 Cr | Rs 2 Cr | -46.55% |
| Net Profit (PAT) | Rs 0.19 Cr | Rs 1 Cr | -85.97% |
The gap between healthy revenue growth and a sharp profit collapse in the Vivo Bio Tech Q1 results FY27 indicates the company’s cost base rose significantly faster than its top line, a pattern worth digging into further through the company’s detailed disclosures.
Vivo Bio Tech Q1 results FY27 Performance Analysis
Get Personalised Guidance from a SEBI-Registered Investment Advisor
The most striking feature of the Vivo Bio Tech Q1 results FY27 is that revenue grew a healthy 14.13% even as PAT collapsed 85.97%, a divergence that points to a sharp rise in operating costs, possibly linked to lab operations, animal husbandry costs, or investment in research capacity that has not yet translated into proportional revenue.
Vivo Bio Tech provides drug development and discovery services including toxicity studies, pharmacological investigations, and preclinical research to pharmaceutical and biotech clients globally, alongside supplying laboratory animal models. This is a specialised, relatively niche contract research business where quarterly profitability has historically shown some volatility.
Historical data shows Vivo Bio Tech’s profit has fluctuated significantly across past quarters, so investors reading the Vivo Bio Tech Q1 results FY27 should view this as part of a longer pattern of volatility in this small cap contract research organisation rather than necessarily a one-off event.
Vivo Bio Tech Q1 results FY27: Key Business Factors
1. Contract Research Business Model
As a preclinical contract research organisation, revenue in the Vivo Bio Tech Q1 results FY27 depends on winning and executing study contracts for pharmaceutical and biotech clients, a business where costs can rise ahead of revenue recognition on new projects.
2. Rising Operating Costs
The sharp gap between revenue growth and profit decline suggests operating costs, potentially including lab animal care, research staff, or facility expenses, grew significantly faster than revenue during the quarter.
3. Historical Profit Volatility
Company disclosures over past years show a pattern of swinging quarterly profitability, meaning the sharp decline in the Vivo Bio Tech Q1 results FY27 fits a broader pattern rather than representing an entirely new trend for this business.
Dividend Details
No dividend was announced along with the Vivo Bio Tech Q1 results FY27. Given the sharp profit decline and the small scale of the business, near-term capital priorities are likely focused on managing costs rather than shareholder payouts.
Vivo Bio Tech Q1 results FY27 Outlook for the Full Year
Whether this quarter’s cost pressure eases in subsequent quarters will be the key factor to watch. Investors should track revenue growth trends in the core contract research business, any disclosed reasons for the margin compression, and whether profitability recovers toward levels seen in stronger recent quarters.
Vivo Bio Tech Stock Performance After the Q1 Results
Download the Univest iOS App or Univest Android App to track Vivo Bio Tech live share price and upcoming quarterly results.
Vivo Bio Tech share price fell 4.13% to close at Rs 24.15 after the Vivo Bio Tech Q1 results FY27, reflecting market disappointment with the sharp profit decline despite the healthy revenue growth.
As a small cap contract research stock with a history of volatile quarterly results, the counter can see sharp price swings on both positive and negative news, and investors should size positions with this volatility in mind.
Key Risks
Investors going through the fine print of the Vivo Bio Tech Q1 results FY27 should also weigh the following risks.
1. Volatile Quarterly Profitability
As seen repeatedly in past quarters and again in the Vivo Bio Tech Q1 results FY27, profit at this company can swing sharply from one quarter to the next, making it difficult to extrapolate a single quarter’s trend.
2. Niche, Relationship-Dependent Business
Contract research revenue depends on winning and retaining client relationships in a specialised, relatively small addressable market, with limited diversification compared with larger pharmaceutical services companies.
3. Small Cap Liquidity and Governance
As a small cap stock, investors should apply extra scrutiny to disclosures and governance practices, and expect limited trading liquidity typical of companies at this scale.
Conclusion
Vivo Bio Tech Q1 results FY27 show a sharp divergence, with revenue up a healthy 14.13% to Rs 14 crore even as PAT collapsed 85.97% to Rs 0.19 crore, reflecting significant cost pressure during the quarter. Revenue growth in the core contract research business is the lone bright spot in the Vivo Bio Tech Q1 results FY27, against a backdrop of volatile historical profitability. Investors should treat this as a high risk small cap and consult a SEBI-registered advisor before acting on the numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Vivo Bio Tech Q1 results FY27
When were the Vivo Bio Tech Q1 results FY27 announced?
Ans. The Vivo Bio Tech Q1 results FY27 were announced on Monday, 13 July 2026, for the quarter ended 30 June 2026.
What is the PAT in Vivo Bio Tech Q1 results FY27?
Ans. The PAT in Vivo Bio Tech Q1 results FY27 fell 85.97% to Rs 0.19 crore from Rs 1 crore in Q1 FY26, despite healthy revenue growth.
What was the revenue in Vivo Bio Tech Q1 results FY27?
Ans. Revenue in the Vivo Bio Tech Q1 results FY27 grew 14.13% year on year to Rs 14 crore from Rs 12 crore.
Why did Vivo Bio Tech profit fall despite revenue growth in Q1 FY27?
Ans. PAT fell sharply in the Vivo Bio Tech Q1 results FY27 even as revenue grew 14.13%, suggesting operating costs, potentially tied to lab operations or research capacity, rose significantly faster than revenue during the quarter.
What does Vivo Bio Tech do as a company?
Ans. Vivo Bio Tech is a Hyderabad based contract research organisation providing drug development, preclinical toxicity studies, pharmacological investigations and laboratory animal models to pharmaceutical and biotech clients.
How did Vivo Bio Tech share price react to the Q1 results FY27?
Ans. Vivo Bio Tech share price fell 4.13% to close at Rs 24.15 after the Vivo Bio Tech Q1 results FY27.
Is Vivo Bio Tech a good buy after the Q1 results FY27?
Ans. The Vivo Bio Tech Q1 results FY27 show a sharp profit decline despite revenue growth, and the company has a history of volatile quarterly results. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.
